CD47

Cluster of Differentiation 47; MER6; OA3

CD47 is a glycoprotein that was first identified in 1990 as a protein that associates with integrins, hence its original name integrin-associated protein. CD47 interacts with SIRPα (CD172a or SHPS-1) and its family member SIRPγ, CD47 also interacts with integrins and secreted glycoprotein extracellular matrix protein thrombospondin-1 (TSP-1). Signaling through the CD47/SIRPα axis plays a role in various homeostatic processes, such as maintenance of erythrocytes, innate immune cells and T cells. Moreover, cancer cells and virus-infected and bacteria-infected cells can upregulate CD47 protein expression to prevent immune-mediated elimination.

CD47 Inhibitors (22)

CD47 Related Products (23):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-16438

RRx-001	Inhibitor	99.16%
RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity.

HY-P99029

Magrolimab	Inhibitor	99.92%
Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer.

HY-143224B

NCGC00138783 TFA	Inhibitor	99.71%
NCGC00138783 TFA is a selective inhibitor targeting CD47/SIRPα axis, with an IC₅₀ of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis.

HY-P99172

CC-90002	Inhibitor
CC-90002 is a humanized anti-CD47 monoclonal antibody (mAb). CC-90002 has a high affinity for binding to CD47 with a subnanomolar K_d value. CC-90002 can be used for the research of hematologic malignancies and solid tumors.

HY-P99175

KWAR 23	Inhibitor	99.80%
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.

HY-P10388

TAX2 peptide	Inhibitor
TAX2 peptide is a dodecapeptide based on molecular docking and simulation design, derived from the cell surface receptor CD47 sequence. TAX2 peptide acts as a selective antagonist of TSP-1 (thromboxin-1) interacting with CD47. TAX2 peptide can promote the binding of TSP-1 to CD36, which leads to the destruction of VEGFR2/KDR/Flk-1 (vascular endothelial growth factor receptor 2) activation, thereby blocking downstream NO (nitric oxide) signaling, demonstrating anti-angiogenic properties. TAX2 peptide can be used to study angiogenesis and tumor cell interactions in the tumor microenvironment.

HY-P10420

RS17	Inhibitor
RS17 is an anti-tumor peptide designed to bind specifically to the CD47 molecule and block the interaction between CD47 and its ligand, SIRPα, on the surface membrane of macrophages. The main regulatory mechanism of RS17 is to prevent CD47 from transmitting selective phagocytosis signals to SIRPα by binding to CD47, so that macrophages do not recognize tumor cells as their own tissue, but phagocytose them as foreign substances, thereby inhibiting immune escape of tumor cells. RS17 can be used to study the mechanism of anti-tumor response and immune escape.

HY-P990132

Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410)	Inhibitor
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is a mouse-derived IgG1, κ type antibody inhibitor, targeting to mouse/rat/human CD47/IAP.

HY-P99026

Lemzoparlimab	Inhibitor
Lemzoparlimab (TJ011133; TJC4) is a humanized anti-CD47 IgG4 antibody. Lemzoparlimab has a strong anti-tumor activity.

HY-P99777

Ontorpacept	Inhibitor	99.57%
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.

HY-P990033

Anzurstobart	Inhibitor	98.53%
Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRPα antibody that blocks the binding of CD47 to SIRPα. Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research.

HY-P99706

Ligufalimab	Inhibitor	98.81%
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity.

HY-P0144

Thrombospondin-1 (1016-1023) (human, bovine, mouse)	Inhibitor	99.08%
Thrombospondin-1 (1016-1023) (human, bovine, mouse), is the C-terminal end of the native sequence of Thrombospondin-1 (TSP-1), is a CD47 agonist peptide.

HY-115983

DMUP	Inhibitor
DMUP is a potent CD47-SIRPα axis inhibitor. DMUP induces apoptosis and increases the macrophage phagocytosis in A549 cells. DMUP decreases the expression of CD47 and SIRPα protein. DMUP shows antitumor activity.

HY-151132

Glutaminyl cyclases-IN-1	Inhibitor
Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent glutaminyl cyclases (QC) inhibitor with IC₅₀ values of 12 nM and 73 nM for human QC and isoQC, respectively. Glutaminyl cyclases-IN-1 can selectively interfere with the interaction of CD47/SIRPα through isoQC inhibition, and enhances the increased phagocytic activity of both THP-1 and U937 macrophages.

HY-143224

NCGC00138783	Inhibitor
NCGC00138783 is a selective inhibitor targeting CD47/SIRPα axis, with an IC₅₀ of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis.

HY-P99533

Urabrelimab	Inhibitor	98.49%
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction.

HY-P3968

Thrombospondin-1 (1016-1021) (human, bovine, mouse)
Thrombospondin-1 (1016-1021) (human, bovine, mouse), a Thrombospondin-1-derived peptide, is a truncated peptide devoid of CD47-binding activity.

HY-143224A

NCGC00138783 free base	Inhibitor
NCGC00138783 free base is a selective inhibitor targeting CD47/SIRPα axis, with an IC₅₀ of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis.

HY-143225

NCGC00538431	Inhibitor
NCGC00538431 is a potent modulator of SIRPα-CD47.

Name
Email *

	Sorry, but the email address you supplied was invalid.